Mesenchymal stem cells for obliterative bronchiolitis
This trial examines the efficacy of treatment of patients with post-lung transplantation bronchiolitis obliterans syndrome with mesenchymal stem cells (MSCs) from related or unrelated human leukocyte antigen (HLA)-identical or HLA-mismatched donors. The expected decrease in forced expiratory volume is halted by treatment and no toxicity occurred.
Read More
Product Information for
Mesenchymal stem cells for obliterative bronchiolitis